Integrating genomic surveillance and ecological modelling to maximise pneumococcal vaccine efficacy

点击翻译按钮获取中文摘要

Streptococcus pneumoniae, or the pneumococcus, is a bacterium found harmlessly living inside the noses of around half of young children in the UK. When they reach other parts of the body, pneumococci can cause harmful infections such as pneumonia, sepsis or meningitis. This is largely attributable to these bacteria having a capsule that protects them from the immune system. In 2010, the UK introduced a vaccine (called PCV13) that protected against 13 of the approximately 100 known capsule types. This eliminated most of these 13 capsule types from both disease and harmless carriage in infants. However, S. pneumoniae strains not affected by the vaccine increased in number to replace the lost capsule types. These strains did not cause disease in infants so frequently, and therefore PCV13 has reduced the amount of childhood pneumococcal disease. However, the replacing strains appear to be more likely to cause disease in adults, who catch the bacteria from healthy children. Hence the amount of adult pneumococcal disease has gone up since PCV13.Public Health England (PHE) lead the evaluation of PCV13 in the UK, and their surveillance of pneumococcal disease means they have the largest collection of well-characterised S. pneumoniae bacteria in the world. This project would select isolates from this collection to study using whole genome sequencing, to understand how the genetics of the bacterial population changed before and after vaccines (PCV13, and similar earlier versions) were introduced. New methods of DNA sequence analysis would be employed to merge UK data with that from research work around the world. These would enable the global migration patterns of S. pneumoniae strains to be traced, identifying the main origins of strains that have recently emerged in the UK.These genetic data will also enable mathematical modelling of the changes in circulating strains caused by PCV13. We have specific hypotheses about the genetics that underlies the changes after vaccination, but previously these have only been tested against bacteria collected from healthy children. This project will expand our models to incorporate the most harmful strains, which are rarely found in the nose. This is critical for understanding why PCV13 had effects on adult disease in the UK that were not common in other countries. This project will also test how accurately these models forecast ongoing trends in S. pneumoniae disease as new surveillance data are collected by PHE. This will help predict whether trends in the overall level of disease are likely to change in the next few years.We would make the model easily accessible to other scientists, such that they could improve and update it. By continually improving the model, we hope to use it as a tool for identifying the risks associated with each of the next generation of vaccines against S. pneumoniae, which are currently being developed. This would help ensure the UK made the right choice to avoid unintended consequences, as occurred with PCV13, and minimise the national burden of S. pneumoniae disease in both infants and adults. Scientists involved in the project serve on UK and international bodies that advise on the use of these vaccines, and therefore our results will be communicated to relevant agencies around the world. We will also explore whether our models and methods could be helpful in analysing other bacteria, particularly focusing on those for which new vaccines are being developed.